Related Experiment Video
Updated: Jul 11, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells
1Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada.
Abstract:
CD9, a member of the tetraspanin family of proteins, is involved in a variety of cellular interactions with many other proteins and molecules. Although CD9 has been implicated in cell fusion, migration and cancer progression, the detailed function of this protein is not completely understood and likely depends on interactions with different protein partners, which are not yet all known. Using co-immunoprecipitation and mass-spectrometric protein sequencing, we have identified in prostate cancer cells, a novel CD9 partner, the 75-kDa protein HSPA9B, also known as mortalin. We further show that introduction and overexpression of wild-type CD9 into human PC-3 prostate cancer cells induces mitotic catastrophe. We also demonstrate, by immunocolocalisation studies, the interaction of CD9 and mortalin in PC-3 cells undergoing mitotic catastrophe. Our results not only identified mortalin as a new CD9 partner, but also clarify the mechanisms by which CD9 may control prostate cancer progression.
Insights
Researchers identified mortalin as a new CD9 protein partner in prostate cancer cells. This discovery clarifies how CD9 influences cancer progression by inducing mitotic catastrophe.
Area of Science:
- Molecular biology
- Cell biology
- Cancer research
Background:
- CD9, a tetraspanin protein, participates in cellular processes like migration and cancer progression.
- The precise functions of CD9 are not fully understood and depend on interactions with various protein partners.
- Identifying novel CD9 partners is crucial for understanding its role in cellular functions and disease.
Purpose of the Study:
- To identify novel protein partners of CD9 in prostate cancer cells.
- To investigate the functional consequences of CD9 overexpression in prostate cancer.
- To elucidate the interaction between CD9 and its novel partner in the context of cancer progression.
Main Methods:
- Co-immunoprecipitation assays to identify interacting proteins.
- Mass-spectrometric protein sequencing for protein identification.
- Overexpression of wild-type CD9 in human PC-3 prostate cancer cells.
- Immunocolocalisation studies to visualize protein interactions.
Main Results:
- Identified HSPA9B (mortalin) as a novel binding partner of CD9 in prostate cancer cells.
- Demonstrated that CD9 overexpression induces mitotic catastrophe in PC-3 cells.
- Confirmed the interaction between CD9 and mortalin in PC-3 cells undergoing mitotic catastrophe.
Conclusions:
- Mortalin is a newly identified CD9 binding partner.
- CD9-mortalin interaction plays a role in inducing mitotic catastrophe in prostate cancer cells.
- This study provides insights into the mechanisms by which CD9 regulates prostate cancer progression.
More Related Videos
15:53Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
